Jeffrey H Lipton, PhD, MD, FRCPC

I am involved in clinical research at the phase I, II and III levels on the therapy of chronic myeloid leukemia. This involves targeted therapy with kinase inhibitors, drugs that may target the CML stem cell and cells that are resistant to other therapies. The interest in targeted therapy extends into the phase II study of signal transduction inhibitors in the therapy of other diseases such as systemic mastocytosis and mast cell leukemia.

The second aspect of my clinical research involves outcome analysis in allogeneic stem cell transplant and the prevention and therapy of side effects. I am particularly interested in donor selection, graft types and therapy of chronic side effects. I am also interested in long term effects on patients who are out beyond the initial post transplant period.

For a list of Dr. Lipton's publications, please visit PubMed or Scopus.


Professor of Medicine, University of Toronto